Hengrui Medicine (600276.SH): Sodium Citrate Hemofiltration Replacement Solution Approved for Listing

Wisdom Wealth APP News, Hengrui Pharmaceuticals (600276.SH) announced that recently, its subsidiary Fujian Shengdi Pharmaceuticals Co., Ltd. received a notice from the National Medical Products Administration (referred to as "NMPA"), approving the listing of the company's citrate sodium blood filtration replacement solution.